NASDAQ
7.85USD
-0.27 (-3.33%)
We have scored 7 news catalysts on Achieve Life Sciences, Inc. (ACHV) over the past 12 months. The biggest single-day move next to one of them came Feb 5, 2026, when ACHV closed −6.2%: “Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch”. Coverage across the window leans positive (average ticker sentiment +0.43). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
799.1M
P/E
—
EPS
—
Beta
2.25
52W range
2.62-8.64
Day range
7.76–8.19
Open
8.06
Prev close
8.12
Volume
698.3K
Avg volume
1.7M
Dividend
0.00
IPO
1995-10-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Achieve Life Sciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ACHV: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
